Mesoblast (NASDAQ:MESO) Upgraded by Cantor Fitzgerald to Strong-Buy Rating

Mesoblast (NASDAQ:MESO) was upgraded by research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research firms also recently issued reports on MESO. Piper Sandler restated an “overweight” rating and set a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Mesoblast has an average rating of “Moderate Buy” and an average price target of $18.00.

Mesoblast Stock Down 4.5 %

Shares of Mesoblast stock opened at $14.71 on Tuesday. Mesoblast has a 1 year low of $1.99 and a 1 year high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The stock has a fifty day moving average price of $18.03 and a 200-day moving average price of $12.25.

Institutional Investors Weigh In On Mesoblast

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in shares of Mesoblast in the third quarter worth about $147,000. XY Capital Ltd bought a new position in Mesoblast in the 3rd quarter worth approximately $244,000. Jane Street Group LLC grew its stake in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares in the last quarter. GAMMA Investing LLC raised its holdings in Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after acquiring an additional 1,213 shares during the period. Finally, Ballentine Partners LLC bought a new stake in Mesoblast during the 4th quarter valued at $222,000. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.